Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials

Atomoxetine is FDA indicated to treat attention deficit hyperactivity disorder (ADHD), and is very commonly prescribed. Because it is a common drug, it is notably important to study the potential for adverse effects, especially serious ones. This study ignores effectiveness and focuses solely on safety.

This study confirmed some of the most well known side effects such as nausea, dry mouth, decreased appetite, insomnia, marginal increases in heart rate and blood pressure, and erectile dysfunction. No side effects seen in this study were previously unknown to occur with atomoxetine. None of the subjects experienced any serious adverse effects, including suicidal thoughts.

The results of this study confirm that atomoxetine is a safe treatment option for ADHD. This study did not examine the effectiveness of the drug in treating ADHD, which often can be highly subjective when comparing ADHD to other disease states. Therefore, the main idea to be elucidated from the results of this study is that atomoxetine is a safe therapy option. If the patient feels that it is working well for them, they can continue to use it without fearing any serious adverse effects, and if other treatment options are not working, they can confidently switch to atomoxetine.

Camporeale A, Porsdal V, De Bruyckere K, et al. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. J Psychopharmacol. 2015: 29(1): 3-14.